New insider activity at NewAmsterdam Pharma Company ( (NAMS) ) has taken place on June 26, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director James Topper has made a significant investment in NewAmsterdam Pharma Company by purchasing 3,780 shares of its stock, valued at $69,451.
Recent Updates on NAMS stock
In the past 24 hours, NewAmsterdam Pharma’s stock has seen positive developments, primarily driven by promising clinical trial results and analyst coverage. Citi initiated coverage with a Buy rating, citing the large unmet need in the LDL cholesterol lowering market and the potential of NewAmsterdam’s obicetrapib as a first-in-class agent. Stifel also initiated coverage with a Buy rating, emphasizing the unique positioning of obicetrapib in the cardiovascular market and its potential differentiation through the PREVAIL trial. Additionally, NewAmsterdam announced positive topline data from the Phase 3 BROADWAY trial, showing significant reductions in Alzheimer’s Disease biomarkers, which supports obicetrapib’s potential as a preventive strategy for Alzheimer’s. These developments have contributed to a favorable outlook for the stock, despite financial performance challenges highlighted by Spark’s AI Analyst, which noted high R&D costs impacting profitability.
Spark’s Take on NAMS Stock
According to Spark, TipRanks’ AI Analyst, NAMS is a Neutral.
The overall stock score reflects significant positive corporate events and developments in clinical trials, offset by financial performance challenges and valuation concerns. While technical analysis suggests potential medium-term strength, the company’s financial challenges and unprofitable status weigh on its valuation.
To see Spark’s full report on NAMS stock, click here.
More about NewAmsterdam Pharma Company
YTD Price Performance: -29.39%
Average Trading Volume: 890,287
Technical Sentiment Signal: Sell
Current Market Cap: $2.06B